
    
      All participants received a 0.5-mL intramuscular dose of their assigned vaccine at Visit 1.
      For participants 3 to < 9 years of age for whom 2 doses of influenza vaccine were recommended
      per Advisory Committee on Immunization Practices (ACIP) guidance, a second dose of Fluzone
      Quadrivalent vaccine (of the same volume) was administered during Visit 2.

      Solicited adverse reaction (AR) information was collected for 7 days after vaccination.
      Unsolicited non-serious adverse event (AE) and serious adverse event (SAE) information was
      collected from Visit 1 to Visit 2 or from Visit 1 to Visit 3 for those participants receiving
      2 doses of study vaccine.

      Immunogenicity was evaluated in all participants prior to vaccination on Day 0 (Visit 1) and
      after the final vaccination on Day 28 for 3 to < 9 year olds and Day 21 days for adults 18
      years and older.
    
  